Discovering and Conducting Joint Research Projects

Yuhan Corporation announced on September 1 that it has signed a Memorandum of Understanding (MOU) with the Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub) to strengthen the innovative new drug pipeline.

(From left) Kim Yeolhong, Head of R&D at Yuhan Corporation, and Park Guseon, Chairman of K-Medi Hub, are taking a commemorative photo after signing a Memorandum of Understanding (MOU) to strengthen the innovative new drug pipeline. Yuhan Corporation

(From left) Kim Yeolhong, Head of R&D at Yuhan Corporation, and Park Guseon, Chairman of K-Medi Hub, are taking a commemorative photo after signing a Memorandum of Understanding (MOU) to strengthen the innovative new drug pipeline. Yuhan Corporation

View original image

This agreement aims to expand joint research opportunities for promising new drug candidates and enhance the national pharmaceutical and biotechnology industry’s competitiveness by combining Yuhan Corporation’s excellent new drug development capabilities with K-MEDI Hub’s new drug research infrastructure and technology support systems.


Through this agreement, the two organizations plan to cooperate in a variety of areas, including: discovering and carrying out joint research projects for new drugs; strengthening R&D capabilities through the exchange of outstanding researchers; mutual technical support using research facilities and cutting-edge equipment; and establishing a medical industry network.


In particular, Yuhan Corporation will further advance its open innovation strategy by utilizing K-MEDI Hub’s expert research personnel and advanced infrastructure, and plans to expand into substantial joint research and technology collaboration in line with concrete future cooperation needs.


Yeolhong Kim, Head of R&D at Yuhan Corporation, stated, “For the development of innovative new drugs, it is essential to organically combine diverse research capabilities and infrastructure. Through cooperation with K-MEDI Hub, we hope to effectively leverage the strengths of both institutions, discover promising new drug development projects, and create successful research and development outcomes.”



Guseon Park, Chairman of K-MEDI Hub, commented, “It is very meaningful to establish a collaborative system for new drug research and development with Yuhan Corporation, a leading pharmaceutical company in Korea. We will do our best to support joint research by utilizing the foundation’s professional workforce and research infrastructure, and contribute to strengthening the competitiveness of Korea’s new drug development industry.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing